July 7 (Reuters) - Eisai Co Ltd and Biogen Inc's Leqembi emerged as the first Alzheimer's treatment to win the U.S. Food and Drug Administration's standard approval on Thursday, a milestone in drug development for a disease that has seen multiple failures in the past. The following is a list of companies that are currently developing treatments that aim to modify the memory-robbing disease: Company Drug or Stage of Mechanism Therapy development & indication Eli Lilly donanemab Designed to and Co Late-stage trial target toxic for early protein plaque Alzheimer’s in the brain known as beta-amyloid and remove brain plaques to slow cognitive decline BioVie Inc NE3107 An oral small Late-stage trial molecule that for mild to aims to inhibit moderate neuroinflammati Alzheimer’s on and insulin resistance AB Science masitinib An oral SA Late-stage study tyrosine kinase for inhibitor that mild-to-moderate targets immune Alzheimer’s cells responsible for neuroinflammati on Annovis buntanetap An Bio Inc Mid-to-late-stage orally-administ trial for moderate ered small Alzheimer's molecule inhibitor of several neurotoxic proteins Cognition CT1812 Oral drug Therapeuti Mid-stage trial designed to cs Inc for bind to a mild-to-moderate specific Alzheimer’s receptor in brain cells, which mediates the attachment of beta-amyloid Coya COYA 301 Designed to Therapeuti Mid-stage trial inhibit cs Inc for molecules mild-to-moderate responsible for Alzheimer’s neuroinflammati on and improve cognitive function Actinogen xanamem Blocks Medical Mid-stage trial production of a Limited for mild-moderate hormone linked Alzheimer's to stress called cortisol inside brain cells and is associated with cognitive impairment AC Immune ACI-24.060 Early- An SA -to-mid stage antibody-based trial for immunotherapy Alzheimer’s vaccine designed to target beta amyloid plaques Biogen Inc BIIB080 An antisense Mid-stage trial oligonucleotide for early-stage therapy Alzheimer’s directed against "tau" proteins Longeveron lomecel-B A cell therapy Inc Mid-stage trial designed to for mild stimulate Alzheimer’s neuroregenerati on and prevent disease progression (Reporting by Pratik Jain and Mariam Sunny in Bengaluru; Editing by Maju Samuel)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
208.9 USD | +3.18% | +7.47% | -19.27% |
Apr. 26 | Guggenheim Adjusts Price Target on Biogen to $255 From $275 | MT |
Apr. 25 | Biogen Inc. Receives Positive CHMP Opinion for TOFIDence (tocilizumab), a Biosimilar Referencing ROACTEMRA | CI |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
6,240 JPY | -0.30% | +5.74% | 11.37B | ||
2,686 PTS | +0.86% | +0.34% | - | ||
733.5 USD | +1.19% | +0.99% | 661B | ||
208.9 USD | +3.18% | +7.47% | 30.42B | ||
18.01 USD | +32.43% | +79.03% | 198M | ||
8.6 USD | +2.02% | +7.50% | 126M | ||
2.35 USD | +2.62% | -0.42% | 221M | ||
1.95 USD | +1.04% | +5.98% | 76.05M | ||
1.936 EUR | +2.76% | -1.63% | 106M | ||
1.75 USD | +4.79% | -8.85% | 12.6M | ||
0.4848 USD | -0.84% | -0.35% | 26.62M | ||
0.03 AUD | +3.45% | +3.45% | 45.52M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.27% | 30.42B | |
-4.66% | 86.13B | |
+1.32% | 39.82B | |
+57.86% | 25.23B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
-9.14% | 11.95B | |
+5.24% | 8.71B | |
-8.42% | 8.12B | |
+2.29% | 7.72B |
- Stock Market
- Equities
- BIIB Stock
- News Biogen Inc.
- Companies in Alzheimer's race after US nod for Eisai/Biogen drug